Figure 2: Hemodynamic Analysis of Control (Low Salt), High Salt Placebo (HFpEF Phenotype), and High-Salt CDC-Treated Rats
GalletRomain
de CoutoGeoffrey
SimsoloEli
ValleJackelyn
SunBaiming
LiuWeixin
TseliouEleni
ZileMichael R.
MarbánEduardo
2019
<b>(A)</b> Representative pressure-volume (PV) loop recordings in control, placebo-treated, and cardiosphere-derived cell (CDC)–treated rats. CDCs normalize tau <b>(B)</b> and −dP/dt minimum <b>(C)</b> in rats with heart failure with preserved ejection fraction without change in dP/dt maximum <b>(D)</b>. PV loop analysis reveals normalization of the slope of the end-diastolic PV relationship (EDPVR) <b>(E)</b>, with no change in the end-systolic PV relationship (ESPVR) <b>(F)</b>. Left ventricular end-diastolic pressure (LVEDP) is normal in the CDC-treated but not the placebo-treated animals <b>(G)</b>. The differences between CDC- and placebo-treated rats are not related to changes in systolic blood pressure (SBP) <b>(H)</b> or diastolic blood pressure (DBP) <b>(I)</b> or heart rate (HR) <b>(J)</b> (n = 8 for control rats and n = 12 for placebo- and CDC-treated rats; for PV loop families, n = 6 for control rats, n = 7 for placebo-treated rats, and n = 8 for CDC-treated rats). *p < 0.05 versus placebo- and CDC-treated rats, †p < 0.05 versus control and CDC-treated rats, and ‡p < 0.05, all by analysis of variance.